CoChat

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors

Open access
Cheng, Haiying, Zou, Yiyu, Ross, Jeffrey S., Wang, Kai, Liu, Xuewen, Halmos, Balazs, Ali, Siraj M., Liu, Huijie, Verma, Amit, Montagna, Cristina, Chachoua, Abraham, Goel, Sanjay, Schwartz, Edward L., Zhu, Changcheng, Shan, Jidong, Yu, Yiting, Gritsman, Kira, Yelensky, Roman, Lipson, Doron, Otto, Geoff, Hawryluk, Matthew, Stephens, Philip J., Miller, Vincent A., Piperdi, Bilal, Perez-Soler, Roman · 2015 · Cancer Discovery
Cited by 104

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

We identified amplification of RICTOR, a key component of the mTOR complex 2 (mTORC2), as the sole actionable genomic alteration in an 18-year-old never-smoker with lung adenocarcinoma. Amplification of RICTOR occurs in 13% of lung cancers (1,016 cases) in The Cancer Genome Atlas and at a similar frequency in an independent cohort of 1,070 patients identified by genomic profiling. In the latter series, 11% of cases harbored RICTOR amplification as the only relevant genomic alteration. Its oncogenic roles were suggested by decreased lung cancer cell growth both in vitro and in vivo with RICTOR ablation, and the transforming capacity of RICTOR in a Ba/F3-cell system. The mTORC1/2 inhibitors were significantly more active against RICTOR-amplified lung cancer cells as compared with other agents targeting the PI3K–AKT–mTOR pathway. Moreover, an association between RICTOR amplification and sensitivities to mTORC1/2 inhibitors was observed. The index patient has been treated with mTORC1/2 inhibitors that led to tumor stabilization for more than 18 months. Significance: RICTOR amplification may define a novel and unique molecular subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors. Cancer Discov; 5(12); 1262–70. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 1225

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-14-0971

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 104

Metadata

Authors
Cheng, H., Zou, Y., Ross, J. S., Wang, K., Liu, X., Halmos, B., Ali, S. M., Liu, H., Verma, A., Montagna, C., Chachoua, A., Goel, S., Schwartz, E. L., Zhu, C., Shan, J., Yu, Y., Gritsman, K., Yelensky, R., Lipson, D., Otto, G., Hawryluk, M., Stephens, P. J., Miller, V. A., Piperdi, B., & Perez-Soler, R.
Venue
Cancer Discovery
Published
2015-12-01
Volume
5
Issue
12
Pages
1262-1270
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2194439446
Cited by
104
References
5
FWCI
7.85
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors. https://app.cochat.ai/papers/10.1158/2159-8290.cd-14-0971
The paper
Cheng, H., Zou, Y., Ross, J. S., Wang, K., Liu, X., Halmos, B., Ali, S. M., Liu, H., Verma, A., Montagna, C., Chachoua, A., Goel, S., Schwartz, E. L., Zhu, C., Shan, J., Yu, Y., Gritsman, K., Yelensky, R., Lipson, D., . . . Perez-Soler, R. (2015). RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-14-0971

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.